LLY vs NVO
Eli Lilly and Company vs Novo Nordisk A/S — AI-powered side-by-side comparison
| Metric | LLY | NVO |
|---|---|---|
| AI Score | 63 | 56 |
| Price | $1,188.57 | $49.48 |
| P/E Ratio | 45.52× | 11.75× |
| ROE | 101.3% | 66.4% |
| Revenue Growth YoY | 47.4% | 8.1% |
| Gross Margin | 82.8% | 81.8% |
| Debt / Equity | 1.60× | 0.67× |
| Dividend Yield | 0.6% | 3.7% |
| RSI (14) | 51.0 | 65.6 |
| Beta | 0.5022 | 1.8569 |
| Expected Upside | — | +25.9% |
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
LLY Full Analysis
NVO Full Analysis